Antibodies to malaria vaccine candidates are associated with chloroquine or sulphadoxine/pyrimethamine treatment efficacy in children in an endemic area of Burkina Faso

Malaria Journal

Volumn 11, Issue , 2012, Pages

  Diarra, Amidou ^a   Nebie, Issa ^a   Tiono, Alfred ^a   Soulama, Issiaka ^a   Ouedraogo, Alphonse ^a   Konate, Amadou ^a   Theisen, Michael ^b   Dodoo, Daniel ^c   Traore, Alfred ^d   Sirima, Sodiomon B ^a,e  

^a Burkina Faso   (Burkina Faso)

^b Statens Serum ^*  (Denmark)

^c University of Ghana   (Ghana)

^d UNIVERSITÉ DE OUAGADOUGOU   (Burkina Faso)

^e Groupe de Recherche Action en Sante   (Burkina Faso)

Author keywords

Antibodies; Chloroquine; GLURP; MSP1 19; MSP3; Sulphadoxine pyrimethamine

Indexed keywords

ACETYLSALICYLIC ACID; CHLOROQUINE; IMMUNOGLOBULIN G; MALARIA VACCINE; PARACETAMOL; PYRIMETHAMINE PLUS SULFADOXINE; ANTIMALARIAL AGENT; BIOLOGICAL MARKER; PROTOZOAL PROTEIN; PROTOZOON ANTIBODY; PYRIMETHAMINE; SULFADOXINE; SULFADOXINE-PYRIMETHAMINE;

ADOLESCENT; ARTICLE; BLOOD SMEAR; BURKINA FASO; CHILD; CLINICAL ASSESSMENT; CONTROLLED STUDY; DRUG EFFICACY; ENDEMIC DISEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN CELL; IMMUNOGLOBULIN BLOOD LEVEL; INFANT; MAJOR CLINICAL STUDY; MALARIA; MALE; NONHUMAN; PRESCHOOL CHILD; PREVALENCE; SCHOOL CHILD; TREATMENT FAILURE; TREATMENT OUTCOME; VENOUS BLOOD; BLOOD; DRUG COMBINATION; DRUG EFFECT; IMMUNOLOGY; MALARIA FALCIPARUM; PARASITOLOGY; PLASMODIUM FALCIPARUM;

ADOLESCENT; ANTIBODIES, PROTOZOAN; ANTIMALARIALS; BIOLOGICAL MARKERS; BURKINA FASO; CHILD; CHILD, PRESCHOOL; CHLOROQUINE; DRUG COMBINATIONS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMMUNOGLOBULIN G; INFANT; MALARIA VACCINES; MALARIA, FALCIPARUM; MALE; PLASMODIUM FALCIPARUM; PROTOZOAN PROTEINS; PYRIMETHAMINE; SULFADOXINE; TREATMENT OUTCOME;

EID: 84858725943     PISSN: None     EISSN: 14752875     Source Type: Journal    
DOI: 10.1186/1475-2875-11-79     Document Type: Article

References (26)

1. Phase I malaria vaccine trial with a long synthetic peptide derived from the merozoite surface protein 3 antigen. Audran R, Cachat M, Lurati F, Soe S, Leroy O, Corradin G, Druilhe P, Spertini F, Infect Immun 2005 73 8017 8026 10.1128/IAI.73.12.8017-8026.2005 16299295
2. Immune responses to Plasmodium falciparum-merozoite surface protein 1 (MSP1) antigen, II. Induction of parasite-specific immunoglobulin G in unsensitized human B cells after in vitro T-cell priming with MSP119. Garraud O, Diouf A, Holm I, Perraut R, Longacre S, Immunology 1999 97 497 505 10.1046/j.1365-2567.1999.00804.x 10447773
3. Progress in the development of malaria vaccines: context and constraints. Brown GV, Parassitologia 1999 41 429 432 10697898
4. Medical need, scientific opportunity and the drive for antimalarial drugs. Ridley RG, Nature 2002 415 686 693 10.1038/415686a 11832957
5. Malaria vaccines: triumphs or tribulations? Ballou WR, Kester KE, Stoute JA, Heppner DG, Parassitologia 1999 41 403 408 10697893
6. Why is it that antimalarial drug treatments do not always work? White NJ, Ann Trop Med Parasitol 1998 92 449 458 10.1080/00034989859429 9683896
7. Progress and challenges for malaria vaccines. Richie TL, Saul A, Nature 2002 415 694 701 10.1038/415694a 11832958
8. Humoral responses to Plasmodium falciparum blood-stage antigens and association with incidence of clinical malaria in children living in an area of seasonal malaria transmission in Burkina Faso, West Africa. Nebie I, Diarra A, Ouedraogo A, Soulama I, Bougouma EC, Tiono AB, Konate AT, Chilengi R, Theisen M, Dodoo D, Remarque E, Bosomprah S, Milligan P, Sirima SB, Infect Immun 2008 76 759 766 10.1128/IAI.01147-07 18070896
9. Do antibody responses to malaria vaccine candidates influenced by the level of malaria transmission protect from malaria? Nebie I, Tiono AB, Diallo DA, Samandoulougou S, Diarra A, Konate AT, Cuzin-Ouattara N, Theisen M, Corradin G, Cousens S, Ouattara AS, Ilboudo-Sanogo E, Sirima BS, Trop Med Int Health 2008 13 229 237 10.1111/j.1365-3156.2007.01994.x 18304269
10. OMS, valuation et surveillance de l'efficacité des antipaludiques pour le traitement P. falciparum non compliqué Genève: OMS/RBM/HTM/200350 2003
11. Cytophilic antibodies to Plasmodium falciparum glutamate rich protein are associated with malaria protection in an area of holoendemic transmission. Lusingu JP, Vestergaard LS, Alifrangis M, Mmbando BP, Theisen M, Kitua AY, Lemnge MM, Theander TG, Malar J 2005 4 48 10.1186/1475-2875-4-48 16194274
12. http://www.stata.com
13. Change of antimalarial first line treatment in Burkina Faso in 2005. Gansané ANI, Soulama I, Tiono A, Diarra A, Konaté AT, Ouédraogo A, Sirima BS, Bull Soc Path Exot 2005 102 31 35
14. Therapeutic efficacy of chloroquine and sequence variation in pfcrt gene among patients with falciparum malaria in central India. Bharti PK, Alam MT, Boxer R, Shukla MM, Gautam SP, Sharma YD, Singh N, Trop Med Int Health 2010 15 33 40 19912592
15. Efficacy of chloroquine plus primaquine treatment and pfcrt mutation in uncomplicated falciparum malaria patients in Rangamati, Bangladesh. Kawai A, Arita N, Matsumoto Y, Kawabata M, Chowdhury MS, Saito-Ito A, Parasitol Int 2011 60 341 346 10.1016/j.parint.2011.05.007 21645634
16. WHO, Guideline for treatment of malaria Geneva: World Health Organization 2006
17. WHO, Malaria site: drug resistance Geneva: World Health Organization 2006
18. Observations on malaria made during treatment of general paralysis. Yorke W, Macfie JWS, Trans R Soc Trop Med Hyg 1924 18 13 34 10.1016/S0035-9203(24) 90664-X
19. Contribution of humoral immunity to the therapeutic response in falciparum malaria. Mayxay M, Chotivanich K, Pukrittayakamee S, Newton P, Looareesuwan S, White NJ, Am J Trop Med Hyg 2001 65 918 923 11791999
20. Soluble and glyco-lipid modified baculovirus Plasmodium falciparum C-terminal merozoite surface protein 1, two forms of a leading malaria vaccine candidate. Bonnet S, Petres S, Holm I, Fontaine T, Rosario S, Roth C, Longacre S, Vaccine 2006 24 5997 6008 10.1016/j.vaccine.2006.04.069 16814434
21. Characterization of the humoral immune response in Plasmodium falciparum malaria. III. Factors influencing the coexpression of antibody isotypes (IgM and IgG-1 to 4). Wahlgren M, Perlmann H, Berzins K, Bjorkman A, Larsson A, Ljungstrom I, Patarroy ME, Perlmann P, Clin Exp Immunol 1986 63 343 353 3516466
22. Treatment of East African Plasmodium falciparum with West African human gammaglobulin. McGregor IA, Carrington SP, Cohen S, Trans R Soc Trop Med Hyg 1963 57 170 175 10.1016/0035-9203(63)90058-0
23. Therapy with a combination of low doses of interleukin 12 and chloroquine completely cures blood-stage malaria, prevents severe anemia, and induces immunity to reinfection. Mohan K, Sam H, Stevenson MM, Infect Immun 1999 67 513 519 9916053
24. Antimalarial drugs clear resistant parasites from partially immune hosts. Cravo P, Culleton R, Hunt P, Walliker D, Mackinnon MJ, Antimicrob Agents Chemother 2001 45 2897 2901 10.1128/AAC.45.10.2897-2901.2001 11557487
25. Naturally acquired antibodies to the glutamate-rich protein are associated with protection against Plasmodium falciparum malaria. Dodoo D, Theisen M, Kurtzhals JA, Akanmori BD, Koram KA, Jepsen S, Nkrumah FK, Theander TG, Hviid L, J Infect Dis 2000 181 1202 1205 10.1086/315341 10720556
26. Mechanisms underlying the monocyte-mediated antibody-dependent killing of Plasmodium falciparum asexual blood stages. Bouharoun-Tayoun H, Oeuvray C, Lunel F, Druilhe P, J Exp Med 1995 182 409 418 10.1084/jem.182.2.409 7629503